A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-263 in Combination With Erlotinib and ABT-263 in Combination With Irinotecan, and Evaluating the Safety of ABT-263 Monotherapy in Subjects With Cancer.

Trial Profile

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-263 in Combination With Erlotinib and ABT-263 in Combination With Irinotecan, and Evaluating the Safety of ABT-263 Monotherapy in Subjects With Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2015

At a glance

  • Drugs Navitoclax (Primary) ; Erlotinib; Irinotecan
  • Indications Cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 04 Jun 2013 Planned end date changed from 1 May 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Dec 2011 Planned end date changed from 1 Dec 2011 to 1 May 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top